




# **Pfizer-BioNTech COVID-19 Vaccination in 12-15 Year Old's**

May 20, 2021

# Housekeeping

- **How to Ask Questions**

- Click on the  icon found at the bottom part of your screen
- A box will open where you can type in questions, comments, indicate sound problems, etc.
- Use this throughout the webinar to ask questions


- **Slides & Recording**

- This webinar is being recorded and a link as well as slides will be emailed out through our listserv as well as posted on our website at: [www.michigan.gov/COVIDvaccineprovider](http://www.michigan.gov/COVIDvaccineprovider)

# Topics Covered

- Public Health Problem: Summary of Available Evidence
- Safety and Efficacy
- Clinical Considerations
- Strong Provider Recommendation

# Public Health Problem: Summary of Available Evidence



# Summary of Available Evidence?

---


## **Adolescents 12-17 years of age are at risk of severe illness from COVID-19**

- Over 1.5 million reported cases and >13,000 hospitalizations to date
  - Hospitalization rate higher than 2009-10 H1N1 pandemic
- Clinical presentation of Multisystem Inflammatory Syndrome in Children (MIS-C) more severe in adolescents than in younger children

## **COVID-19 in Adolescents may also indirectly impact others' health**

- Adolescents contribute to transmission in households and communities
  - Including older adults at higher risk for COVID-19
- Adolescents represent an increasing proportion of recent COVID-19 cases

**Safety and Efficacy**



# Safety: Reactogenicity

## Pfizer-BioNTech COVID-19 Vaccine, 12-15 Year Old's

- Local reactions within 7 days occurred in 91% of vaccine recipients
  - Pain at the injection site most common
- Systemic reactions within 7 days occurred in 91% of vaccine recipients
  - Fatigue and headache most common
- Most symptoms resolved in 1-2 days
- Severe reactions were more common in vaccine recipients; a grade  $\geq 3$  reaction (interfering with daily life) was reported by 10.7% of vaccinated vs. 1.9% placebo
  - Fatigue, fever, headache most common
- No deaths were reported among trial participants

# Safety Cont..

## Pfizer-BioNTech COVID-19 Vaccine, 12-15 Year Old's

- No cases of anaphylaxis reported in the adolescent (12-15 years of age) study participants
- No cases of Bell's Palsy or facial paralysis reported in adolescent participants
- Among adolescents 12-15 years of age, 7 (0.6%) in the vaccine group had lymphadenopathy, compared to 1 (0.1%) participant
  - Most lymphadenopathy was local (arm or neck region), occurred on the same side as vaccination, and occurred within 2-10 days



# Clinical Efficacy

## Pfizer-BioNTech COVID-19 vaccine, 12-15 year olds


- The clinical trial demonstrated efficacy against symptomatic, laboratory-confirmed COVID-19. The efficacy was **100%**

Population	Events/Vaccine (n/N)	Events/Placebo (n/N)	Vaccine efficacy (95% CI)
Primary outcome			
No evidence of prior infection, $\geq 7$ d post dose 2	0/1001 <sup>a</sup>	16/972 <sup>a</sup>	100.0% <sup>b</sup>
Secondary outcomes			
$\pm$ evidence of prior infection, $\geq 7$ d post dose 2	0/1109 <sup>a</sup>	18/1094 <sup>a</sup>	100.0% <sup>c</sup>
All available efficacy ( $\pm$ evidence of prior infection, post dose 1)	3/1120 <sup>a</sup>	35/1119 <sup>a</sup>	91.4% (72.2%, 97.4%)

a. Number of subjects at risk for the endpoint; b. With a standard continuity correction of 0.5 applied, the estimated VE (95% CI) is 97.1% (51.0%, 99.8%)

c. With a standard continuity correction of 0.5 applied, the estimated VE (95% CI) is 97.3% (55.8%, 99.8%)

# Clinical Considerations



# Interim Clinical Considerations

- These considerations apply only to the vaccine products currently authorized in the United States (i.e., Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines)
- Clinical considerations have been updated to include guidance for adolescents and recommendations regarding vaccine coadministration and vaccination after Multisystem Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A)

## Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States



Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination

### Reference Materials

Summary Document for Interim Clinical Considerations 

Summary Document for Interim Clinical Considerations poster 

COVID-19 Vaccine Administration Errors and Deviations 

COVID-19 Vaccine Administration Errors and Deviations Poster 

### Get Email Updates

To receive email updates about this page, enter your email address:

[What's this?](#)

### Summary of recent changes (last updated May 14, 2021):

- Updated information for authorized age groups to include vaccination of adolescents ages 12-15 years with Pfizer-BioNTech COVID-19 vaccine.
- Updated information on coadministration of COVID-19 vaccines with other vaccines.



# Pfizer-BioNTech Dosing and Administration

---

<b>Authorized age groups</b>	<b>≥ 12 years</b>
Number of doses in series	2 doses
Interval between 1 <sup>st</sup> and 2 <sup>nd</sup> doses*	3 weeks
Dose volume	0.3 ml
Route	Intramuscular

---

\*If it is not feasible to adhere to the recommended interval, the second dose may be administered up to 6 weeks (42 days) after the first dose.

# Coadministration

---

- COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days

# Coadministration Cont..

---

- It is unknown whether reactogenicity is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines
- When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider:
  - Whether the patient is behind or at risk of becoming behind on recommended vaccines
  - Their risk of vaccine-preventable diseases (e.g., during an outbreak or occupational exposures)
  - The reactogenicity profile of the vaccines

<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

# Coadministration Cont..

- If multiple vaccines are administered at a single visit, administer each injection in a different injection site
- For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection
- Best practices for multiple injections include:
  - Label each syringe to identify the vaccine it contains
  - Separate injection sites by 1 inch or more, if possible
  - Administer COVID-19 and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible

# Considerations for People with a History of MIS-C or MIS-A

- People with a history of MIS-C\* or MIS-A\* may choose to be vaccinated
- Considerations for vaccination may include:
  - Clinical recovery from MIS-C or MIS-A, including return to normal cardiac function
  - Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)
  - Level of COVID-19 community transmission and personal risk of reinfection
  - Lack of safety data of COVID-19 vaccines following these illnesses
  - Timing of any immunomodulatory therapies

\*Multisystem Inflammatory Syndrome in Children (MIS-C) and adults (MIS-A)

<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>



# Considerations for People with a History of MIS-C or MIS-A

- Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, people with a history of MIS-C or MIS-A **should consider delaying vaccination until they have recovered from illness and for 90 days after the date of diagnosis of MIS-C or MIS-A**, recognizing that the risk of reinfection and, therefore, the benefit from vaccination, might increase with time following initial infection.

<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html>

<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

# Contraindications for COVID-19 Vaccine

---

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Immediate allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine
- Known polysorbate allergy is no longer a contraindication to mRNA vaccination but is a contraindication to Janssen COVID-19 vaccine and thus, a precaution to mRNA COVID-19 vaccination

# Syncope


---

- Syncope (fainting) may occur in association with any injectable vaccine
- Procedures should be in place to prevent falling injuries and manage syncopal reactions following vaccination
- All people are recommended to be observed following vaccination for at least 15 minutes; patients should be seated or lying down during the observation period to decrease the risk for injury should they faint. If syncope develops, patients should be observed until symptoms resolve

# Observation Period Following Vaccination

- History of immediate allergic reaction (any severity) to a vaccine or injectable therapy
- Contraindication to a different type of COVID-19 vaccine
- History of anaphylaxis (due to any cause)

All other persons




30 minutes



15 minutes

**Strong Provider  
Recommendation**





# Surveys of Parents (intent to have children vaccinated)

- Among parents surveyed, **46-60%** plan to get their children vaccinated<sup>1-4</sup>
- Reasons for not vaccinating<sup>2</sup>:
  - not sure it will be safe (59%)
  - vaccine developed too quickly (59%)
  - don't trust info being published about the vaccine (48%)
  - won't trust right away (44%)
  - don't have enough info (43%)
- Parents reported similar or slightly lower intent to vaccinate their children compared to intent to vaccinate themselves<sup>3,4</sup>


1. Axios/Ipsos April 2-5; Axios/Ipsos April 16-19; Calarco and Anderson preprint; WebMD March 2021.

2. National Parents Union Survey January 2021

3. Simonson M, Baum M, Lazer D, et al. The COVID States Project #45: Vaccine hesitancy and resistance among parents.OSF Preprints, 19 Mar. 2021. <https://doi.org/10.31219/osf.io/e95bc>

4. Parents Together March 2021 Survey

## Acceptability: Comfort with adolescent receiving COVID-19 vaccine at each site




# Making a Strong Recommendation to Get a COVID-19 Vaccine

---


- Make it clear to your patients that you recommend COVID-19 vaccination for them
- Tell your patients how important COVID-19 vaccines are to protect their health, as well as the health of their family and friends
- COVID-19 vaccines are new, and it's understandable that your patients may have questions. Your answers can help them make an informed decision about getting vaccinated
- Make it clear that you understand they may have questions, and you want to answer them, so they feel confident in choosing to get vaccinated
- If you are not currently offering COVID-19 vaccination, send them to [www.vaccines.gov](http://www.vaccines.gov) to find a location



# Resources



## COVID-19 Vaccine Provider Guidance and Educational Resources



This webpage will house materials to support COVID-19 Vaccine Providers in successful implementation of the COVID-19 Vaccination Program. Be sure to "bookmark" this page and check back frequently for updates!

### GENERAL COVID-19 VACCINE RESOURCES

[COVID-19 Vaccination Clinic Preparation Checklist & Resource Toolkit](#) - **NEW**

[MDHHS COVID-19 Vaccination Interim Prioritization Guidance](#)

[CDC COVID-19 Vaccine Resources for Healthcare Professionals](#)

- Vaccine administration, storage and handling, reporting, and patient education for each specific vaccine

[COVID-19 Vaccine Training Module](#)

- Self-paced module with certificate of completion (no CE)
- MDHHS strongly recommends that all COVID-19 Vaccine Providers complete this training.

[CDC HCP Vaccine Administration Resource Library](#)

### CONTENT-SPECIFIC COVID-19 RESOURCES

[Webinars](#)

- [Upcoming Noontime Knowledge: Thursday May 20, 2021 at 12:00 pm](#)

[Enrollment](#)

[Redistribution](#)

[Vaccine Billing and Vaccine Code Sets](#)

[Product-Specific Information & EUAs](#)

[Pfizer](#)

[Moderna](#)

[Janssen \(Johnson & Johnson\)](#)

MDHHS  
COVID-19 Provider  
Guidance and Education Website  
[www.michigan.gov/covidvaccineprovider](http://www.michigan.gov/covidvaccineprovider)

# MDHHS

## “Teens and COVID-19 Vaccines” Parent Handout

[https://www.michigan.gov/documents/coronavirus/Teens\\_and\\_COVID-19\\_Vaccines\\_v6\\_725127\\_7.pdf](https://www.michigan.gov/documents/coronavirus/Teens_and_COVID-19_Vaccines_v6_725127_7.pdf)

- The most common side effects are pain, redness or swelling at the injection site, tiredness, low-grade fever, or muscle aches for a day or two after getting the vaccine.
- Side effects tend to be more common after the second dose.
- It takes two weeks after the last dose of COVID-19 vaccine to get the best immune response and to be considered fully vaccinated.
- Keep your COVID-19 vaccination card as proof of your vaccination. You may need to show it to keep a history of your card.

Learn more: [Getting Your COVID-19 Vaccine](#)

### Benefits of being vaccinated

People who are fully vaccinated can start doing many things again.

- Are allowed to gather with others without a mask
- Don't need to get tested before or after travel.
- May not be required to participate in testing programs
- Don't need to quarantine after being exposed to someone with COVID-19

### Requesting a copy of vaccine records

**Need to request a copy of your child or dependent's records.** The Michigan Department of Health and Human Services (MDHHS) can help you request a copy of your child's or dependent's Official State of Michigan Immunization Records can be requested from your child's or dependent's doctor or the Local Health Department. [mmr.org/public](https://www.michigan.gov/mdhhs/0,4570,7-293_7-294_7-295_7-296_7-297_7-298_7-299_7-300_7-301_7-302_7-303_7-304_7-305_7-306_7-307_7-308_7-309_7-310_7-311_7-312_7-313_7-314_7-315_7-316_7-317_7-318_7-319_7-320_7-321_7-322_7-323_7-324_7-325_7-326_7-327_7-328_7-329_7-330_7-331_7-332_7-333_7-334_7-335_7-336_7-337_7-338_7-339_7-340_7-341_7-342_7-343_7-344_7-345_7-346_7-347_7-348_7-349_7-350_7-351_7-352_7-353_7-354_7-355_7-356_7-357_7-358_7-359_7-360_7-361_7-362_7-363_7-364_7-365_7-366_7-367_7-368_7-369_7-370_7-371_7-372_7-373_7-374_7-375_7-376_7-377_7-378_7-379_7-380_7-381_7-382_7-383_7-384_7-385_7-386_7-387_7-388_7-389_7-390_7-391_7-392_7-393_7-394_7-395_7-396_7-397_7-398_7-399_7-400_7-401_7-402_7-403_7-404_7-405_7-406_7-407_7-408_7-409_7-410_7-411_7-412_7-413_7-414_7-415_7-416_7-417_7-418_7-419_7-420_7-421_7-422_7-423_7-424_7-425_7-426_7-427_7-428_7-429_7-430_7-431_7-432_7-433_7-434_7-435_7-436_7-437_7-438_7-439_7-440_7-441_7-442_7-443_7-444_7-445_7-446_7-447_7-448_7-449_7-450_7-451_7-452_7-453_7-454_7-455_7-456_7-457_7-458_7-459_7-460_7-461_7-462_7-463_7-464_7-465_7-466_7-467_7-468_7-469_7-470_7-471_7-472_7-473_7-474_7-475_7-476_7-477_7-478_7-479_7-480_7-481_7-482_7-483_7-484_7-485_7-486_7-487_7-488_7-489_7-490_7-491_7-492_7-493_7-494_7-495_7-496_7-497_7-498_7-499_7-500_7-501_7-502_7-503_7-504_7-505_7-506_7-507_7-508_7-509_7-510_7-511_7-512_7-513_7-514_7-515_7-516_7-517_7-518_7-519_7-520_7-521_7-522_7-523_7-524_7-525_7-526_7-527_7-528_7-529_7-530_7-531_7-532_7-533_7-534_7-535_7-536_7-537_7-538_7-539_7-540_7-541_7-542_7-543_7-544_7-545_7-546_7-547_7-548_7-549_7-550_7-551_7-552_7-553_7-554_7-555_7-556_7-557_7-558_7-559_7-560_7-561_7-562_7-563_7-564_7-565_7-566_7-567_7-568_7-569_7-570_7-571_7-572_7-573_7-574_7-575_7-576_7-577_7-578_7-579_7-580_7-581_7-582_7-583_7-584_7-585_7-586_7-587_7-588_7-589_7-590_7-591_7-592_7-593_7-594_7-595_7-596_7-597_7-598_7-599_7-600_7-601_7-602_7-603_7-604_7-605_7-606_7-607_7-608_7-609_7-610_7-611_7-612_7-613_7-614_7-615_7-616_7-617_7-618_7-619_7-620_7-621_7-622_7-623_7-624_7-625_7-626_7-627_7-628_7-629_7-630_7-631_7-632_7-633_7-634_7-635_7-636_7-637_7-638_7-639_7-640_7-641_7-642_7-643_7-644_7-645_7-646_7-647_7-648_7-649_7-650_7-651_7-652_7-653_7-654_7-655_7-656_7-657_7-658_7-659_7-660_7-661_7-662_7-663_7-664_7-665_7-666_7-667_7-668_7-669_7-670_7-671_7-672_7-673_7-674_7-675_7-676_7-677_7-678_7-679_7-680_7-681_7-682_7-683_7-684_7-685_7-686_7-687_7-688_7-689_7-690_7-691_7-692_7-693_7-694_7-695_7-696_7-697_7-698_7-699_7-700_7-701_7-702_7-703_7-704_7-705_7-706_7-707_7-708_7-709_7-710_7-711_7-712_7-713_7-714_7-715_7-716_7-717_7-718_7-719_7-720_7-721_7-722_7-723_7-724_7-725_7-726_7-727_7-728_7-729_7-730_7-731_7-732_7-733_7-734_7-735_7-736_7-737_7-738_7-739_7-740_7-741_7-742_7-743_7-744_7-745_7-746_7-747_7-748_7-749_7-750_7-751_7-752_7-753_7-754_7-755_7-756_7-757_7-758_7-759_7-760_7-761_7-762_7-763_7-764_7-765_7-766_7-767_7-768_7-769_7-770_7-771_7-772_7-773_7-774_7-775_7-776_7-777_7-778_7-779_7-780_7-781_7-782_7-783_7-784_7-785_7-786_7-787_7-788_7-789_7-790_7-791_7-792_7-793_7-794_7-795_7-796_7-797_7-798_7-799_7-800_7-801_7-802_7-803_7-804_7-805_7-806_7-807_7-808_7-809_7-810_7-811_7-812_7-813_7-814_7-815_7-816_7-817_7-818_7-819_7-820_7-821_7-822_7-823_7-824_7-825_7-826_7-827_7-828_7-829_7-830_7-831_7-832_7-833_7-834_7-835_7-836_7-837_7-838_7-839_7-840_7-841_7-842_7-843_7-844_7-845_7-846_7-847_7-848_7-849_7-850_7-851_7-852_7-853_7-854_7-855_7-856_7-857_7-858_7-859_7-860_7-861_7-862_7-863_7-864_7-865_7-866_7-867_7-868_7-869_7-870_7-871_7-872_7-873_7-874_7-875_7-876_7-877_7-878_7-879_7-880_7-881_7-882_7-883_7-884_7-885_7-886_7-887_7-888_7-889_7-890_7-891_7-892_7-893_7-894_7-895_7-896_7-897_7-898_7-899_7-900_7-901_7-902_7-903_7-904_7-905_7-906_7-907_7-908_7-909_7-910_7-911_7-912_7-913_7-914_7-915_7-916_7-917_7-918_7-919_7-920_7-921_7-922_7-923_7-924_7-925_7-926_7-927_7-928_7-929_7-930_7-931_7-932_7-933_7-934_7-935_7-936_7-937_7-938_7-939_7-940_7-941_7-942_7-943_7-944_7-945_7-946_7-947_7-948_7-949_7-950_7-951_7-952_7-953_7-954_7-955_7-956_7-957_7-958_7-959_7-960_7-961_7-962_7-963_7-964_7-965_7-966_7-967_7-968_7-969_7-970_7-971_7-972_7-973_7-974_7-975_7-976_7-977_7-978_7-979_7-980_7-981_7-982_7-983_7-984_7-985_7-986_7-987_7-988_7-989_7-990_7-991_7-992_7-993_7-994_7-995_7-996_7-997_7-998_7-999_800)

### Related resources

Age Groups and Vaccines: Teens/College. [chhp.edu/c/agogroups-and-vaccines/teens-college-students](https://www.michigan.gov/mdhhs/0,4570,7-293_7-294_7-295_7-296_7-297_7-298_7-299_7-300_7-301_7-302_7-303_7-304_7-305_7-306_7-307_7-308_7-309_7-310_7-311_7-312_7-313_7-314_7-315_7-316_7-317_7-318_7-319_7-320_7-321_7-322_7-323_7-324_7-325_7-326_7-327_7-328_7-329_7-330_7-331_7-332_7-333_7-334_7-335_7-336_7-337_7-338_7-339_7-340_7-341_7-342_7-343_7-344_7-345_7-346_7-347_7-348_7-349_7-350_7-351_7-352_7-353_7-354_7-355_7-356_7-357_7-358_7-359_7-360_7-361_7-362_7-363_7-364_7-365_7-366_7-367_7-368_7-369_7-370_7-371_7-372_7-373_7-374_7-375_7-376_7-377_7-378_7-379_7-380_7-381_7-382_7-383_7-384_7-385_7-386_7-387_7-388_7-389_7-390_7-391_7-392_7-393_7-394_7-395_7-396_7-397_7-398_7-399_7-400_7-401_7-402_7-403_7-404_7-405_7-406_7-407_7-408_7-409_7-410_7-411_7-412_7-413_7-414_7-415_7-416_7-417_7-418_7-419_7-420_7-421_7-422_7-423_7-424_7-425_7-426_7-427_7-428_7-429_7-430_7-431_7-432_7-433_7-434_7-435_7-436_7-437_7-438_7-439_7-440_7-441_7-442_7-443_7-444_7-445_7-446_7-447_7-448_7-449_7-450_7-451_7-452_7-453_7-454_7-455_7-456_7-457_7-458_7-459_7-460_7-461_7-462_7-463_7-464_7-465_7-466_7-467_7-468_7-469_7-470_7-471_7-472_7-473_7-474_7-475_7-476_7-477_7-478_7-479_7-480_7-481_7-482_7-483_7-484_7-485_7-486_7-487_7-488_7-489_7-490_7-491_7-492_7-493_7-494_7-495_7-496_7-497_7-498_7-499_7-500_7-501_7-502_7-503_7-504_7-505_7-506_7-507_7-508_7-509_7-510_7-511_7-512_7-513_7-514_7-515_7-516_7-517_7-518_7-519_7-520_7-521_7-522_7-523_7-524_7-525_7-526_7-527_7-528_7-529_7-530_7-531_7-532_7-533_7-534_7-535_7-536_7-537_7-538_7-539_7-540_7-541_7-542_7-543_7-544_7-545_7-546_7-547_7-548_7-549_7-550_7-551_7-552_7-553_7-554_7-555_7-556_7-557_7-558_7-559_7-560_7-561_7-562_7-563_7-564_7-565_7-566_7-567_7-568_7-569_7-570_7-571_7-572_7-573_7-574_7-575_7-576_7-577_7-578_7-579_7-580_7-581_7-582_7-583_7-584_7-585_7-586_7-587_7-588_7-589_7-590_7-591_7-592_7-593_7-594_7-595_7-596_7-597_7-598_7-599_7-600_7-601_7-602_7-603_7-604_7-605_7-606_7-607_7-608_7-609_7-610_7-611_7-612_7-613_7-614_7-615_7-616_7-617_7-618_7-619_7-620_7-621_7-622_7-623_7-624_7-625_7-626_7-627_7-628_7-629_7-630_7-631_7-632_7-633_7-634_7-635_7-636_7-637_7-638_7-639_7-640_7-641_7-642_7-643_7-644_7-645_7-646_7-647_7-648_7-649_7-650_7-651_7-652_7-653_7-654_7-655_7-656_7-657_7-658_7-659_7-660_7-661_7-662_7-663_7-664_7-665_7-666_7-667_7-668_7-669_7-670_7-671_7-672_7-673_7-674_7-675_7-676_7-677_7-678_7-679_7-680_7-681_7-682_7-683_7-684_7-685_7-686_7-687_7-688_7-689_7-690_7-691_7-692_7-693_7-694_7-695_7-696_7-697_7-698_7-699_7-700_7-701_7-702_7-703_7-704_7-705_7-706_7-707_7-708_7-709_7-710_7-711_7-712_7-713_7-714_7-715_7-716_7-717_7-718_7-719_7-720_7-721_7-722_7-723_7-724_7-725_7-726_7-727_7-728_7-729_7-730_7-731_7-732_7-733_7-734_7-735_7-736_7-737_7-738_7-739_7-740_7-741_7-742_7-743_7-744_7-745_7-746_7-747_7-748_7-749_7-750_7-751_7-752_7-753_7-754_7-755_7-756_7-757_7-758_7-759_7-760_7-761_7-762_7-763_7-764_7-765_7-766_7-767_7-768_7-769_7-770_7-771_7-772_7-773_7-774_7-775_7-776_7-777_7-778_7-779_7-780_7-781_7-782_7-783_7-784_7-785_7-786_7-787_7-788_7-789_7-790_7-791_7-792_7-793_7-794_7-795_7-796_7-797_7-798_7-799_7-800_7-801_7-802_7-803_7-804_7-805_7-806_7-807_7-808_7-809_7-810_7-811_7-812_7-813_7-814_7-815_7-816_7-817_7-818_7-819_7-820_7-821_7-822_7-823_7-824_7-825_7-826_7-827_7-828_7-829_7-830_7-831_7-832_7-833_7-834_7-835_7-836_7-837_7-838_7-839_7-840_7-841_7-842_7-843_7-844_7-845_7-846_7-847_7-848_7-849_7-850_7-851_7-852_7-853_7-854_7-855_7-856_7-857_7-858_7-859_7-860_7-861_7-862_7-863_7-864_7-865_7-866_7-867_7-868_7-869_7-870_7-871_7-872_7-873_7-874_7-875_7-876_7-877_7-878_7-879_7-880_7-881_7-882_7-883_7-884_7-885_7-886_7-887_7-888_7-889_7-890_7-891_7-892_7-893_7-894_7-895_7-896_7-897_7-898_7-899_7-900_7-901_7-902_7-903_7-904_7-905_7-906_7-907_7-908_7-909_7-910_7-911_7-912_7-913_7-914_7-915_7-916_7-917_7-918_7-919_7-920_7-921_7-922_7-923_7-924_7-925_7-926_7-927_7-928_7-929_7-930_7-931_7-932_7-933_7-934_7-935_7-936_7-937_7-938_7-939_7-940_7-941_7-942_7-943_7-944_7-945_7-946_7-947_7-948_7-949_7-950_7-951_7-952_7-953_7-954_7-955_7-956_7-957_7-958_7-959_7-960_7-961_7-962_7-963_7-964_7-965_7-966_7-967_7-968_7-969_7-970_7-971_7-972_7-973_7-974_7-975_7-976_7-977_7-978_7-979_7-980_7-981_7-982_7-983_7-984_7-985_7-986_7-987_7-988_7-989_7-990_7-991_7-992_7-993_7-994_7-995_7-996_7-997_7-998_7-999_800)

Questions and Answers about COVID-19 vaccines.



# COVID-19 Vaccine

Safe. Effective. No Cost.

**FIND A VACCINE NEAR YOU**

Or call the **COVID-19 Hotline** at 888-535-6136 (press 1) 8 a.m. to 5 p.m., Monday-Friday, 8 a.m. to 1 p.m., Saturday and Sunday.

**ACCESS THE STATE'S VACCINE DATA**

**GET YOUR QUESTIONS ANSWERED**

**ATTEND AN UPCOMING TOWN HALL**

## RESOURCES

**COVID-19 VACCINE  
QUESTIONS AND ANSWERS  
FOR PARENTS**

**TEENS AND COVID-19  
VACCINES**

**LOCAL HEALTH  
DEPARTMENT VACCINE  
INFORMATION**

**COVID-19 VACCINES &  
FETAL CELLS**

**FOOD PROCESSING &  
AGRICULTURAL WORKERS**

**COMMUNITY OUTREACH  
PILOT PROGRAM**

**PROTECT MICHIGAN  
COMMISSION**

**INTERIM COVID-19  
VACCINATION STRATEGY**

**SOCIAL VULNERABILITY  
AND COVID-19**

**VACCINE ALLOCATION  
PLANNING**

**VACCINE TESTIMONIALS**

**COVID-19 VACCINE  
COMMUNICATION  
MATERIALS**

[www.michigan.gov/covidvaccine](http://www.michigan.gov/covidvaccine)

# CDC Resources by Vaccine Product

Learn more with CDC's COVID-19 vaccine tools and resources. Find information for COVID-19 vaccination administration, storage, reporting, training and education

<https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>

## U.S. COVID-19 Vaccine Product Information

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Pfizer-BioNTech

Moderna

Janssen/J&J

### Requirements, Trainings, and Resources

Vaccine Storage and Handling Toolkit

COVID-19 Vaccine Quick Reference Guide for Healthcare Professionals 

Training and Education

COVID-19 Vaccine Quick Reference Guide for Healthcare Professionals Poster 

Provider Requirements and Support


FAQs for Healthcare Professionals

# CDC Toolkit for Medical Centers, Clinics, and Clinicians

<https://www.cdc.gov/vaccines/covid-19/health-systems-communication-toolkit.html>

# Pediatric Healthcare Professionals COVID19 Vaccination Toolkit

<https://www.cdc.gov/coronavirus/2019-nCoV/vaccines/toolkits/pediatrician.html>



**COVID-19 Vaccine for Preteens and Teens**

CDC recommends vaccination for everyone 12 years and older.

**Why does my child need a COVID-19 vaccine?**  
COVID-19 vaccines help protect kids from getting COVID-19. Getting vaccinated can help prevent serious illness even if they do get COVID-19.


**When should my child be vaccinated?**  
All kids who are 12 years and older should get a COVID-19 vaccine. Talk to their doctor about getting it as soon as possible.


**Are COVID-19 vaccines safe for my child?**  
Yes. COVID-19 vaccination provides safe and effective protection against the virus that causes COVID-19. The COVID-19 vaccines have been under the most intensive safety monitoring in U.S. history.

The Pfizer-BioNTech COVID-19 Vaccine is now available for everyone 12 and older. In the clinical trial for children ages 12 through 15, the Pfizer-BioNTech vaccine was 100% effective at preventing COVID-19 with symptoms. In addition, children's immune systems respond to the vaccine in a way similar to those of older teens and young adults. No safety concerns were identified in the clinical trial.

**Before, during and after your child's vaccination:**

- Your child will need 2 shots given 3 weeks (21 days) apart to get the best protection.
- Tell the doctor or nurse about any allergies your child may have.
- Comfort your child during the appointment.
- To prevent fainting and injuries related to fainting, your child should sit or lie down for 15 minutes after the vaccine is given.
- After your child's COVID-19 vaccination, you will be asked to stay for 15 minutes to watch for any severe allergic reaction and need immediate treatment.

 **CDC**  
COVID-19 | 05/12/21



**Answering Your Questions About the Safety and Effectiveness of COVID-19 Vaccines**

**Do clinical trial results show whether vaccines are effective?**  
Yes, clinical trials provide data and information about how well a vaccine prevents a disease and how safe it is. The Food and Drug Administration (FDA) evaluates these data, along with information from the manufacturer, to assess the safety and effectiveness of the vaccine. FDA then decides whether to approve the vaccine or authorize it for emergency use in the United States.


**Why would the effectiveness of vaccines be different after the clinical trials?**  
Many factors can affect how well a vaccine works in real-world conditions. These factors can include how a vaccine is transported and stored and how the vaccine is given. Vaccine effectiveness can also be affected by differences in the underlying medical conditions of people vaccinated as compared to those vaccinated in the clinical trials.


CDC is assessing how well COVID-19 vaccines work in real-world conditions. Some real-world assessments observe both people who get vaccinated and those who don't to see how many people in each group become ill with COVID-19. Some assessments look at how COVID-19 vaccine effectiveness differs for people who are partially vaccinated compared to those who are fully vaccinated.

Assessments of vaccine effectiveness can also provide important information about how well a vaccine is working in groups of people who were either not included or were not well represented in clinical trials, and how well vaccines protect against COVID-19 variants.

**How are experts evaluating the COVID-19 vaccine effectiveness in real-world conditions?**  
Experts are working on many types of assessments to determine vaccine effectiveness in real-world conditions. Each study type uses a different method:

- Case-control assessments** include cases (people who have COVID-19) and controls (people who do not have COVID-19). People who agree to participate in a case-control assessment provide information on whether they received a COVID-19 vaccine or not. Experts look to see if the cases were less likely to be vaccinated than controls, which would show the vaccine is working.
- Test-negative design assessments** enroll people who are seeking medical care for symptoms that could be due to COVID-19. In this special type of case-control assessments, experts compare the COVID-19 vaccination status of those who test positive (meaning they have COVID-19) to those who test negative (meaning they do not have COVID-19).



 **CDC**  
COVID-19 | 05/13/21

[www.cdc.gov/coronavirus/vaccines](https://www.cdc.gov/coronavirus/vaccines)



# Thank You!

Next “Noontime Knowledge” Update: June 3, 2021, at 12:00p.m. Topic: TBD

Please watch your email for an updated link and topic!

[www.michigan.gov/COVIDvaccineprovider](http://www.michigan.gov/COVIDvaccineprovider)

